2nd Quarter - Amendment

AMERICAN ASSOCIATION FOR CANCER RESEARCH for AMERICAN ASSOCIATION FOR CANCER RESEARCH

Firm
Client
Income
—
Expenses
$100,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report Jul 18, 2022 $100,000 Replaced
2nd Quarter - Amendment (this page) Oct 19, 2022 $100,000 Yes

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

FY 2023 Appropriations for the National Institutes of Health FY 2023 Appropriations for the Centers for Disease Control and Prevention FY 2023 Appropriations for the Food and Drug Administration FY 2023 Appropriations for the Congressionally Directed Medical Research Programs at the Department of Defense

LobbyistCovered position, as disclosed
DANA MILLER ACTON —
MARC JOHNSON —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medical/Disease Research/Clinical Labs MED

Cancer research Oncology product review at the FDA Pediatric research and cancer care Clinical trials Diversity in clinical trials

LobbyistCovered position, as disclosed
DANA MILLER ACTON New —
MARC JOHNSON —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Tobacco TOB

Tobacco control measures E-cigarette regulation

LobbyistCovered position, as disclosed
DANA MILLER ACTON New —
MARC JOHNSON —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

Cancer health disparities HPV-related cancers - prevention, screening, diagnosis and treatment HPV vaccination Cancer survivorship

LobbyistCovered position, as disclosed
DANA MILLER ACTON New —
MARC JOHNSON —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.